Quantcast

Latest OncoGenex Pharmaceuticals Inc. Stories

2011-03-07 05:00:00

BOTHELL, WA and VANCOUVER, March 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and full year 2010 financial results will be released on Thursday, March 10, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide a 2011 corporate outlook....

2011-02-28 06:56:00

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m....

2011-02-17 08:00:00

BOTHELL, WA/>, and VANCOUVER/>, Feb. 17/> /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) has been named as one of the top ten companies in the biotech industry in the March 2011/> issue of Fast Company, as part of the magazine's annual list of the "Most Innovative Companies."  OncoGenex is uniquely focused on developing novel and diverse molecular product candidates that target mechanisms of resistance to cancer treatments, and that have the potential to...

2011-02-08 05:00:00

BOTHELL, WA, and VANCOUVER, Feb. 8 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will provide a corporate presentation at the 13th Annual BIO CEO & Investor Conference on Monday, February 14 at 4:30 p.m. ET at the Waldorf Astoria Hotel in New York City. The corporate presentation will be webcast live and can be accessed through the Investor Relations page of the OncoGenex...

2010-11-08 05:00:00

BOTHELL, WA, and VANCOUVER, Nov. 8 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of Michelle Burris to the position of executive vice president, operations and chief financial officer. Ms. Burris, a seasoned public company executive, brings over 20 years of financial and operations management experience to OncoGenex.  Ms. Burris, who will join the company in this capacity on January 3, 2011, is currently a member of the...

2010-11-04 15:01:00

Conference Call on Thursday, November 4, 2010 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, Nov. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the three and nine months ended September 30, 2010 and provided an update on the business, the recent financing and anticipated use of proceeds to advance the product pipeline. "The public offering in October was a transformative...

2010-10-22 12:01:00

BOTHELL, WA, and VANCOUVER, Oct. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has completed a public offering of 3,174,602 units at a price to the public of $15.75 per unit for an aggregate offering amount of $50 million, as previously announced on October 18, 2010. The net proceeds to OncoGenex, after underwriting discounts and commissions and other offering expenses, from the sale of the units is approximately $46.7 million. The...

2010-10-21 05:00:00

BOTHELL, WA and VANCOUVER, Oct. 21 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter financial results will be released on Thursday, November 4, 2010, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's third quarter results and provide an update on the business, the recent financing and anticipated use of proceeds to advance the product...

2010-10-19 08:00:00

BOTHELL, WA, and VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it has priced a public offering of 3,174,602 units, with each unit consisting of one share of the Company's common stock and one-half (1/2) of one warrant, at a purchase price of $15.75 per unit for an aggreate offering amount of $50 million. The net proceeds to OncoGenex, after underwriting discounts and commissions and other offering expenses, from the sale...

2010-10-18 15:01:00

BOTHELL, WA and VANCOUVER, Oct. 18 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock.  OncoGenex intends to use the net proceeds from the offering primarily to advance its product pipeline, including its lead program, custirsen, and OGX-427, which is currently in clinical development as a treatment for prostate cancer and bladder...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.